CogState (ASX:CGS) share price crashes 20% on quarterly update

CogState shares tanked today despite the company reporting record-breaking results.
The post CogState (ASX:CGS) share price crashes 20% on quarterly update appeared first on The Motley Fool Australia. –

Key points

The CogState share price fell as low as $1.84 today — 20% down on yesterday’s close
The neuroscience technology company released a quarterly update today
Clinical sale contracts have increased by 141%, hitting a new record

The CogState Limited (ASX: CGS) share price flatlined today after the company released a business and investor update this morning.

At market close, the CogState share price was down 15.95% to $1.95. The share price bounced back in late afternoon trade after declining to an intraday low of $1.84.

Whilst CogState reported record figures for contracts and revenue, its shares continued the bleeding today as they have all month. The CogState share price began 2022 at $2.55 on the first day of ASX trading on 4 January. That’s a 23% dip to date.

So what exactly did CogState report? Let’s take a closer look.

CogState investors unenthused by results

CogState aims to provide tools to measure brain health and cognition in order to assist in research and remedies.

Today’s announcement reveals just a small number of business financials, with a more detailed report set to be released on 24 February.

CogState’s business update revealed:

Revenue for 2Q22 up 40% at $10.8 million against its prior corresponding period (PCP)
Revenue for 1H22 up 67% at $23.1 million compared to PCP
$24.6 million in net cash as of 31 December

Record figures for CogState

In its investor report, CogState revealed a number of records hit during the quarter, including:

A 141% increase in executed clinical sale contracts amounting to $54.5 million
A 78% increase in contracted future revenue at $132.9 million
A 67% increase in group revenue at $23.1 million

The company said Alzheimer’s trials have continued to boost its clinical sales contracts. In 1H22, the disease accounted for 90% of CogState sales contracts.

What else is news?

Just recently, CogState announced that its brain assessment tool, CogMate, is to be marketed in Taiwan and Hong Kong through its Taiwanese subsidiary, Eisai Taiwan Inc.

CogMate is a multilingual tool that measures cognitive performance. It can be used with smartphones and other smart devices.

CogState hopes the product will assist in the “self assessment and prevention” of diseases such as dementia, with ageing populations in mind.

Exposure to other countries, including Singapore, is on the horizon.

Cogstate share price snapshot

Over the past 12 months, the CogState share price has leapt 75%.

There was a 50% jump in June after the company announced its Alzheimer’s therapeutic had received accelerated approval based on its clinical trials. At that time, the CogState share price was $1.40. It also saw a sharp 8% jump in September to $1.87.

The company has a market capitalisation of just over $402 million and a price-to-earnings ratio (P/E) of 55.25.

The post CogState (ASX:CGS) share price crashes 20% on quarterly update appeared first on The Motley Fool Australia.

Should you invest $1,000 in CogState right now?

Before you consider CogState, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CogState wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

More reading

What’s happening to the Wesfarmers share price (ASX:WES) this year?

Own AGL (ASX:AGL) shares? JP Morgan is overweight, tips 23% upside in 2022

Own CBA (ASX: CBA) shares? Here’s what’s happening with the big bank this week

The Hot Chili (ASX:HCH) share price cooled by 7% today. Here’s why

2 cheap ASX 200 shares rated as top buys

Motley Fool contributor Alice de Bruin has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!